Published in Am J Kidney Dis on January 01, 2005
Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol (2011) 1.14
Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res (2009) 1.05
Protein-energy wasting and mortality in chronic kidney disease. Int J Environ Res Public Health (2011) 0.98
CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction. Cell Signal (2012) 0.93
Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovasc Diabetol (2015) 0.90
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract (2008) 0.87
Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol (2008) 0.85
Prolonged pain to hospital time is associated with increased plasma advanced oxidation protein products and poor prognosis in patients with percutaneous coronary intervention for ST-elevation myocardial infarction. Heart Vessels (2010) 0.83
Structural effects of methionine oxidation on isolated subdomains of human fibrin D and αC regions. PLoS One (2014) 0.82
High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol (2011) 0.81
AOPPs and the progression of kidney disease. Kidney Int Suppl (2011) (2014) 0.79
Effluent free radicals are associated with residual renal function and predict technique failure in peritoneal dialysis patients. Perit Dial Int (2012) 0.79
Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy. J Diabetes Investig (2012) 0.78
An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study. Oxid Med Cell Longev (2015) 0.77
Differences in coagulation between hemodialysis and peritoneal dialysis. Perit Dial Int (2013) 0.77
Assessment of oxidative, inflammatory, and fibrinolytic biomarkers and DNA strand breakage in hypercholesterolemia. Inflammation (2013) 0.76
In vitro and in vivo antioxidant properties of the plant-based supplement greens+™. Int J Mol Sci (2011) 0.76
Associations of GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients. BMC Nephrol (2014) 0.76
Plasma protein-bound di-tyrosines as biomarkers of oxidative stress in end stage renal disease patients on maintenance haemodialysis. BBA Clin (2017) 0.75
Advanced Glycation End Products Evolution after Pancreas-Kidney Transplantation: Plasmatic and Cutaneous Assessments. Oxid Med Cell Longev (2016) 0.75
Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients; a randomized clinical trial. J Nephropathol (2015) 0.75
Advanced Oxidation Protein Products-Modified Albumin Induces Differentiation of RAW264.7 Macrophages into Dendritic-Like Cells Which Is Modulated by Cell Surface Thiols. Toxins (Basel) (2017) 0.75
Vitamin D Levels Decline with Rising Number of Cardiometabolic Risk Factors in Healthy Adults: Association with Adipokines, Inflammation, Oxidative Stress and Advanced Glycation Markers. PLoS One (2015) 0.75
CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol (2017) 0.75
Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes. J Am Soc Nephrol (2003) 3.25
Central pulse pressure and mortality in end-stage renal disease. Hypertension (2002) 3.02
Arterial stiffness and kidney function. Hypertension (2004) 2.45
Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int (2003) 2.21
Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol (2005) 2.20
Antiviral immunity in Drosophila requires systemic RNA interference spread. Nature (2009) 2.15
Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension (2005) 2.08
AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int (2003) 1.91
Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol (2006) 1.90
Peculiar morphology of stones in primary hyperoxaluria. N Engl J Med (2008) 1.68
Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant (2005) 1.61
Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice. Hepatology (2006) 1.61
Late referral: loss of chance for the patient, loss of money for society. Nephrol Dial Transplant (2002) 1.59
Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation (2002) 1.58
Drug-induced renal calculi: epidemiology, prevention and management. Drugs (2004) 1.58
Plasma-induced endothelial oxidative stress is related to the severity of septic shock. Crit Care Med (2007) 1.57
IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis (2011) 1.53
Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity (2002) 1.53
Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant (2007) 1.53
Increased pasma S-nitrosothiol concentrations predict cardiovascular outcomes among patients with end-stage renal disease: a prospective study. J Am Soc Nephrol (2004) 1.51
Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol (2004) 1.44
Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant (2003) 1.43
Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int (2006) 1.43
Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. J Clin Invest (2015) 1.43
Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant (2002) 1.40
Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int (2012) 1.38
Influence of body size on urinary stone composition in men and women. Urol Res (2006) 1.36
RNAi-mediated immunity provides strong protection against the negative-strand RNA vesicular stomatitis virus in Drosophila. Proc Natl Acad Sci U S A (2010) 1.34
Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol Res (2004) 1.25
RNA-mediated interference and reverse transcription control the persistence of RNA viruses in the insect model Drosophila. Nat Immunol (2013) 1.24
Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens (2008) 1.20
Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int (2009) 1.16
The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int (2005) 1.16
Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation (2005) 1.14
In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension (2007) 1.12
Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant (2011) 1.11
Annexin 1 cleavage in activated neutrophils: a pivotal role for proteinase 3. J Biol Chem (2007) 1.10
Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta (2004) 1.10
Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens (2004) 1.10
Prognostic significance of arterial stiffness measurements in end-stage renal disease patients. Curr Opin Nephrol Hypertens (2002) 1.06
The role of neutrophils and monocytes in innate immunity. Contrib Microbiol (2008) 1.06
In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. J Innate Immun (2010) 1.05
Chloride transport in nasal ciliated cells of cystic fibrosis heterozygotes. Am J Respir Crit Care Med (2005) 1.03
Local shear stress and brachial artery functions in end-stage renal disease. J Am Soc Nephrol (2007) 1.02
Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol (2012) 1.02
Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol (2004) 1.02
Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets? Nephrol Dial Transplant (2012) 1.02
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS One (2012) 1.01
Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant (2006) 1.01
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol (2011) 1.01
Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J Pharmacol Exp Ther (2010) 0.99
High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant (2005) 0.99
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis (2008) 0.99
Relationships between carbonation rate of carbapatite and morphologic characteristics of calcium phosphate stones and etiology. Urology (2009) 0.99
Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl (2003) 0.98
Stone formation and pregnancy: pathophysiological insights gained from morphoconstitutional stone analysis. J Urol (2010) 0.97
Peroxiredoxin 6 fails to limit phospholipid peroxidation in lung from Cftr-knockout mice subjected to oxidative challenge. PLoS One (2009) 0.97
Diabetes and nephrolithiasis. Curr Diab Rep (2007) 0.96
Inspection of the binding sites of proteinase3 for the design of a highly specific substrate. J Med Chem (2006) 0.95
Oxidative stress and chronic renal failure: markers and management. J Nephrol (2002) 0.95
Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int (2004) 0.95
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol (2008) 0.95
Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int (2005) 0.94
Coronin-1 is associated with neutrophil survival and is cleaved during apoptosis: potential implication in neutrophils from cystic fibrosis patients. J Immunol (2009) 0.93
Automated degenerate PCR primer design for high-throughput sequencing improves efficiency of viral sequencing. Virol J (2012) 0.93
Structures of human proteinase 3 and neutrophil elastase--so similar yet so different. FEBS J (2010) 0.93
Multiple-family group treatment for English- and Vietnamese-speaking families living with schizophrenia. Psychiatr Serv (2006) 0.93
Arterial structure and function in end-stage renal disease. Curr Hypertens Rep (2008) 0.93
Dietary salt restriction accelerates atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis (2005) 0.92
Computational prediction of the binding site of proteinase 3 to the plasma membrane. Proteins (2008) 0.91
Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. J Urol (2008) 0.90
Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J (2011) 0.90
Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int (2005) 0.90
Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens (2006) 0.89
Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis (2013) 0.89
Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics (2006) 0.88
Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res (2003) 0.86
Immune system dysregulation in uremia: role of oxidative stress. Blood Purif (2002) 0.86
Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab (2014) 0.85
[Continued late referral of patients with chronic kidney disease. Causes, consequences, and approaches to improvement]. Presse Med (2006) 0.85